A carregar...
Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study
OBJECTIVE: To assess the safety of rapidly dissolving buprenorphine/naloxone sublingual tablets (BNX-RDT) in opioid-dependent patients. METHODS: This open-label, 24-week extension study enrolled patients who completed primary trials of BNX-RDT. Daily tablet doses ranged from 5.7 to 17.1 mg. The prim...
Na minha lista:
| Publicado no: | J Addict Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5457835/ https://ncbi.nlm.nih.gov/pubmed/28353467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/ADM.0000000000000301 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|